Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pneumococcal 13-valent conjugate vaccine + tetanus toxoid
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This is not a single combination product but rather two separate vaccines that can be administered concomitantly. Pneumococcal 13-valent conjugate vaccine (Prevenar 13/Prevnar 13) provides active immunization against 13 serotypes of *Streptococcus pneumoniae* (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Tetanus toxoid is a component in various vaccines that provides immunity against tetanus. Clinical studies have demonstrated that when administered together, the immune responses to both vaccines are maintained without interference.
- Brand names
- Prevenar 13 + tetanus toxoid
- Other names
- Prevnar 13 + tetanus toxoid
02
Targets
CPS (Streptococcus pneumoniae capsular polysaccharide)TT (Tetanus toxoid)T cell receptor recognizing tetanus toxoid-derived peptidesBCR (Immunoglobulin G B Cell Receptor)
Beyond the preview
Go deeper on pneumococcal 13-valent conjugate vaccine + tetanus toxoid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pneumococcal 13-valent conjugate vaccine + tetanus toxoid.